Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Neurosurgery. 2013 May;72(5):777–795. doi: 10.1227/NEU.0b013e318286fdc8

Mechanisms of Stroke after Intracranial Angioplasty and Stenting in the SAMMPRIS Trial

Colin P Derdeyn 1, David Fiorella 2, Michael J Lynn 3, Zoran Rumboldt 4, Harry J Cloft 5, Daniel Gibson 1, Tanya N Turan 6, Bethany F Lane 3, L Scott Janis 7, Marc I Chimowitz 6; for the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators
PMCID: PMC3696348  NIHMSID: NIHMS474450  PMID: 23328689

Abstract

Background

Enrollment in the Stenting and Aggressive Medical Management for the Prevention of stroke in Intracranial Stenosis (SAMMPRIS) trial was halted owing to higher than expected 30-day stroke rates in the stenting arm. Improvement in peri-procedural stroke rates from angioplasty and stenting for intracranial atherosclerotic disease (ICAD) requires an understanding of the mechanisms of these events.

Objective

To identify the types and mechanisms of peri-procedural stroke after angioplasty and stenting for ICAD.

Methods

Patients that suffered a hemorrhagic or ischemic stroke or a cerebral infarct with temporary signs (CITS) within 30 days of attempted angioplasty and stenting in SAMMPRIS were identified. Study records, including case report forms, procedure notes, and imaging were reviewed. Strokes were categorized as ischemic or hemorrhagic. Ischemic strokes were categorized as perforator territory, distal embolic, or delayed stent thrombosis. Hemorrhagic strokes were categorized as subarachnoid or intraparenchymal. Causes of hemorrhage (wire perforation, vessel rupture) were recorded.

Results

Three patients suffered an ischemic stroke after diagnostic angiography. Two were unrelated to the procedure. Twenty-one patients suffered an ischemic stroke (n= 19) or CITS (n=2) within 30 days of angioplasty and stenting. Most (n=15) were perforator territory and many of these occurred after angiographically successful angioplasty and stenting of the basilar artery (n = 8). Six patients suffered subarachnoid hemorrhage (three from wire perforation) and seven a delayed intraparenchymal hemorrhage.

Conclusion

Efforts at reducing complications from angioplasty and stenting for ICAD must focus on reducing the risks of regional perforator infarction, delayed intraparenchymal hemorrhage, and wire perforation.

Keywords: Angioplasty and Stenting, Stroke, Hemorrhage

Introduction

The efficacy of angioplasty and stenting for patients with symptomatic intracranial atherosclerotic disease was recently evaluated in the Stenting and Aggressive Medical Management for the Prevention of Recurrent stroke in Intracranial Stenosis (SAMMPRIS) trial. 1 This trial is the largest prospective study to date in this population. Enrollment was stopped early owing to a higher rate of 30-day stroke and death in the stenting arm relative to aggressive medical management. Two hundred and twenty-four patients were randomized to the stenting arm and thirty-three (14.7%) suffered a symptomatic stroke within 30 days of enrollment. An additional four patients suffered an intracranial hemorrhage with symptoms lasting less than 24 hours or a cerebral infarction with temporary signs (CITS) within 30 days of the stenting procedure.2

Detailed statistical analyses of the relationship between clinical, procedural, and operator variables and the risk of 30-day adverse events have already been published.2, 3 The aims of the present study are to investigate the specific nature and mechanism of individual events, to describe the frequencies of the different mechanisms, and to describe the clinical and imaging features of each event to provide a more complete understanding of the peri-procedural events in the trial. These data will be critical for developing an understanding of how patient selection or devices could be improved to reduce the risk of perioperative stroke from angioplasty and stenting for symptomatic intracranial atherosclerotic disease (ICAD).

Methods

SAMMPRIS is an ongoing randomized, multi-center clinical trial funded by the National Institute of Neurological Disorders and Stroke.1, 4 Enrollment and randomization are complete but medical treatment and follow-up of enrolled patients is continuing until March 2013. The study design has been published.1, 4 Eligibility criteria included either transient ischemic attack (TIA) or non-disabling stroke within 30 days prior to enrollment attributable to angiographically-verified 70% to 99% stenosis of a major intracranial artery.

PTAS Procedure

The Gateway PTA Balloon Catheter and Wingspan Stent System (Boston Scientific Corporation, Stryker Neurovascular, Fremont CA) was used for PTAS in the trial. Specific aspects of the study protocol for PTAS procedure, post-procedure care, and aggressive medical management (same in both arms of the trial) have been published. 1, 5 The PTAS procedure was mandated for within three business days of randomization. A 600 mg loading dose between 6 – 24 hours before PTAS was allowed if the patient was not on daily clopidogrel (75 mg) for five days prior to PTAS. Systemic heparinization during PTAS was required with a target activated clotting time (ACT) of between 250 and 300 seconds.

Central Adjudication of Outcome after PTAS

Clinical evaluations of treated patients were required at study entry and four days (by study coordinator) and 30 days after enrollment. The patient was examined by a study neurologist and brain imaging was typically performed if a peri-procedural stroke was suspected. All potential study endpoints were adjudicated by central physician investigators blinded to treatment assignment. 1,2

Ischemic stroke was defined as a new focal neurological deficit of sudden onset that lasted at least 24 hours and was not associated with a hemorrhage on brain imaging (computed tomography (CT) or magnetic resonance imaging (MRI)). If symptoms lasted for less than 24 hours and was associated with a new infarct on brain imaging, the event was classified as a CITS. Hemorrhagic stroke was defined as parenchymal, subarachnoid, or intraventricular hemorrhage detected by CT or MRI that was associated with new neurological signs or symptoms lasting > 24 hours or a seizure. These were primary endpoints. Hemorrhagic stroke associated with symptoms or signs (excluding seizure) less than 24 hours in duration were not considered primary endpoints.

Subtype Classification of Events

The present study is a retrospective and post-hoc analysis of data collected in the trial. Patients with centrally-adjudicated 30-day ischemic stroke, symptomatic hemorrhagic stroke, asymptomatic hemorrhagic stroke or CITS after randomization to the stenting arm were identified. Study records, including case report forms, scanned documents such as procedure and progress notes and discharge or death summaries, and records of central end-point adjudication were reviewed. In addition, electronically archived (iSite, Phillips, Eindhoven Netherlands) baseline, procedural and post-procedure brain and vascular images were reviewed.

All peri-procedural (within 30 days after randomization) ischemic strokes, CITS and hemorrhagic strokes were categorized by consensus of the three primary investigators (DF, CD, MC) based on an assessment of the available imaging and clinical data. Hemorrhagic strokes were classified as subarachnoid hemorrhages (SAH) when the bleeding was predominantly subarachnoid and the presentations were evident immediately after the procedure, or as reperfusion hemorrhages when the bleeding was predominantly intraparenchymal (ICH) and within the vascular distribution of the stented vessel. Ischemic strokes were further categorized as local perforator territory (covered by the stent), distal embolic, and delayed stent thrombosis based on imaging findings and the clinical deficits. Ischemic strokes were categorized as perforator occlusions if the infarct(s) and symptoms could be localized to the distribution supplied by perforating vessels arising within the margins of the stent, or embolic if the infarct was in a territorial distribution distal to the treated lesion and the symptoms were explained by the distal infarct. If a patient had lesions on imaging in local perforator and distal territories, but the symptoms were consistent with perforator ischemia only, the event was classified as a perforator event. When more than one mechanism contributed to the clinical findings, the stroke was described as mixed. Delayed stent occlusion was diagnosed if there was imaging or other presumptive evidence of stent occlusion.

Images and procedure reports were carefully reviewed for any evidence of mechanical or procedural causes of the hemorrhagic or ischemic event, including wire perforation, vessel rupture for hemorrhage and vessel dissection for ischemic stroke.

Tables of the data collected for each individual patient were created based on the results of these reviews (Tables 14). Tabulated data included age and gender, the nature of the qualifying event (stroke, TIA and major symptoms), baseline imaging findings if available, location of the symptomatic stenosis, time from qualifying event to procedure, pertinent details of the procedure, nature and timing of the complication, presumed mechanism of the event, and the 30-day outcome (modified Rankin Score, mRS).

Table 1.

Angiogram-only strokes

Patient
Numb
er
Age/
Gend
er
Qualifying
Event
Baseline
Imaging
Location of
Stenotic
Artery
Timing QE
to
Procedure
(days)
Procedural and Stroke Details Mechanism of
Stroke
Associated
with Clinically
Relevant Infarct
30-day
Outco
me
35 57/M Stroke:
Ataxia
And
weakness
MR (+
infarct)
Vertebrobasil
ar junction
7 80% lesion at VBJ by diagnostic
catheter angiogram
Angiogram under anesthesia showed
significant reduction in stenosis, now
<60%. New PICA evident on angio
(Figure 2)
New vision loss post angio. New
occipital and posterior inferior
cerebellar artery territory strokes on
repeat MR
Embolic
Complication
of angio
mRS 4
36 70/F Stroke:
dysarthria,
arm and
leg
weakness
No
baseline
MR or CT
submitte
d
Basilar 5 Diagnostic angiogram (3 days after
stroke) demonstrated 98% basilar
stenosis
Therapeutic (for planned
angioplasty) angiogram showed
interval occlusion at the site of
tenosis
Retrograde filling from PComA.
atient awoke stable
Acute stroke in territory 3 days later.
New infarctions by MR in pons and
midbrain
Delayed
thrombo-
embolic
Died 3
days
after
angio
37 74/F Stroke:
face, arm
and leg
weakness,
aphasia
CT (+
infarct)
Internal
carotid artery
4 Catheter angiogram (2 days after
stroke) demonstrated 89% cavernous
ICA stenosis
Treatment angiogram showed
complete occlusion
Acute stroke in the territory 5 days
later while in rehab. (Figure 2, MR
ADC maps)
Delayed
thrombo-
embolic
mRS 4

Infarct size: 1.5 cm or less – small, 1.5 to 3.0 cm – medium. No petechial hemorrhage unless otherwise noted. Corresponding images described in the

“Procedural and Stroke Details” are shown in Figure 2 by patient number, unless indicated otherwise.

M = male; F = female; MR = magnetic resonance; CT = computed tomography; mRS = modified Rankin score; QE = Qualifying event; ADC = apparent diffusion coefficient)

Table 4.

Subarachnoid Hemorrhage

Patient
Numbe
r
Age/
Gend
er
Qualifyin
g Event
Baseline
Imaging
Locatio
n of
Stenotic
Artery
Parent
artery
diameter
(per site)
Timing and Details of
Procedure
Post
Procedural
details
Mechanis
m
30-day
Modifie
d
Rankin
Scale
29 54/F TIA:
Episode
of
aphasia
for a few
minutes
MR (same
day): no acute
lesion, small old
cortical strokes
in territory
M1 2.21 mm 28 days after TIA.
Subtle extravasation
seen in distal inferior
division near tip of
exchange wire after
stent placement.
Confirmed
by DSA-CT.
Required
decompres
sive
craniectomy.
Wire
perforati
on
5
30 74/M Stroke:
slurred
speech
noted on
awakeni
ng.
Dysarthri
a and
right
facial
droop
persisted
more
than 24
hours
MR (same
day): Acute
pontine
infarction
VBJ 2.00 mm 11 days after stroke. No
SAH identified during
procedure. Lost guide
catheter during
exchange for stent and
repositioned guide
catheter after placing
micro- exchange wire
into SCA
Acute SAH
centered in
superior
vermian
region on
DSA-CT.
Required
Urgent
ventriculost
omy.
Developed
extensive
brainstem
infarction
Wire
Perforatio
n
5
31 69/F TIA:
dizziness
upper
extremit
y numbne
ss
MR (5 months
prior): Normal
Distal
VA
4.00 mm 22 days after TIA and
diagnostic angio.
Interval occlusion of
distal VA. Isolated VB
system with chronic
contralateral VA
occlusion and absent
PComAs. Abciximab
administered. Lesion
was crossed with SL-10
catheter. Location in
basilar confirmed. 3.5 ×
9 mm Gateway
inflated. Active
extravasation seen at
PICA origin (Figure).
SAH persisted after
reversal and 60 minutes
of balloon inflation.
Treated successfully
with
nBCA
Long
complicated
hospital
course
Vessel
rupture
5
32 57/ M Stroke:
dysarthri
a, L
facial,
UE, LE
weaknes
s
MR (same
day): acute
corona
radiate,
subinsular
infarction in the
territory
Petrous
ICA
3.90 24 days after stroke.
Small amount of
extravasation noted in
distal branche near tip
of exchange wire.
Branch occluded with
coils.
LUE and
Facial
weakness,
and
dysarthria
postop. CT
shows some
SAH and
infarction
around coils
Wire
Perforatio
n
0
33 50/F TIA:
Recurre
nt
episodes
of upper
extremit
y
weaknes
s.
MR (same
day):
no acute lesion.
Small old
cortical and subcortical
infarctions in
the territory.
M1 2.30 mm 4 days after TIA.
Extravasation evident
on angio after stent
deployment.
Appeared to arise from
two distal MCA
branches, one that had
been accessed with
the guidewire. This was
treated with Onyx.
After a delay of 15
minutes, no further
extravasation was
noted from the second
branch.
Post op MR
showed an
acute
posterior
division
MCA
infarction
and sylvian
SAH. Initial
global
aphasia but
made
substantial
improvement
Unknown 2
Asymptomatic SAH
34 76/F TIA
(CITS): 2
Syncopa
l Episodes
consider
ed TIAs
by site
MR (2 days
post): acute
caudate stroke
M1 3.50 mm 9 days after CITS. No
SAH identified during
procedure. Unable to
advance stent into M1
segment. Angioplasty
repeated and second
stent attempt failed.
Acute SAH
in sylvian
fissure on DSA-CT.
Asymptoma
tic
Unknown 0

Notes: Baseline MR not required by protocol.

Figures (Figures 1 and 2) were constructed using images submitted from the site: baseline qualifying events, pre and post-procedural angiograms, and relevant representative images of the hemorrhage or infarction.

Figure 1.

Figure 1

Composite figure of pre and post-angioplasty and stenting angiogram, and brain imaging demonstrating the location and extent of ischemic injury for each individual patient. The number corresponds to the patient number in table 2. Descriptions of the procedure and relevant findings on the images is found in the table under the description of the heading “procedure and stroke details”

Figure 2.

Figure 2

Composite figure of pre and post-angioplasty and stenting angiogram, and brain imaging demonstrating the location and extent of hemorrhage or ischemic injury for each individual patient. The number corresponds to the patient number in tables 1, 3, and 4. Descriptions of the procedure and relevant findings on the images is found in the table under the description of the headings “timing and details of procedural” and “Post-procedural details”.

Results

Angiography-Only Strokes

Two hundred and twenty patients underwent attempted angioplasty and stenting. The procedure was aborted in six prior to any intervention owing to the findings on catheter angiography and in one case when attempts to cross the lesion with a wire were unsuccessful. Three of these seven patients suffered an ischemic stroke (Table 1, patients 35–37, Figure 2). One was a definite procedural embolic stroke (patient 35) in a patient randomized to stenting based on prior imaging but found to have less than 50% stenosis at the time of the planned PTAS procedure. The remaining two patients suffered strokes days later (patients 36 and 37). Both of these patients had developed an interval complete occlusion of the target vessel between enrollment and the planned intervention.

Procedural Ischemic Strokes

Twenty-one ischemic events (19 ischemic strokes and 2 CITS) occurred in the remaining 213 patients (Table 2, Patients 1 −21, Figure 1). Of the 21 events, 14 were evident on emerging from general anesthesia (patients 1 – 14). Eleven of the fourteen primarily involved local perforators (and resulted in clinical syndromes attributable to the perforator infarction), two were embolic (patients 7 and 10) and one was mixed embolic and perforator territory owing to acute intraprocedural stent thrombosis (patient 11, post angio). Technical difficulties were noted in two of the 11 perforator territory strokes that were evident immediately after the procedure (patient 1 (small V4 dissection flap) and patient 8 (difficult vertebral artery access). Post-angioplasty angiographic images were unremarkable in all 11 cases of perforator infarction. Distal embolic occlusion was evident on the post-angioplasty images in one case (patient 7, missing left superior cerebellar artery on post angioplasty angiogram). This patient also received no plavix load and ACTs were not recorded during the procedure.

Table 2.

Acute Ischemic Stroke

Patient Age/
Gender
Qualifying
Event
Baseline
Imaging
Location
of
Stenotic
Artery
and %
stenosis
Timing QE
to
Procedure
(days)
Procedural and Stroke Details Mechanism of
Stroke
Associated with
Clinically
Relevant Infarct
30-day
Outcome
1 80/F TIA: slurred
speech,
ataxia,
vertigo, LUE
and LLE
numbness
MR: no
acute/
subacute
infarcts. Old
R pontine
infarct
Basilar;
71%
11 Small V4 dissection, otherwise
uncomplicated procedure
24 hours after procedure:
diplopia,slurred speech, gait
instability. MR showed: new
infarct in R pons(perforators),
small R cerebellar infarcts
(probable embolus to jailed
AICA) and small bilateral
occipital lobes (distal emboli).
Occlusion of
local perforators
to pons
mRS 1
(1 at study
entry)
2 58/M Stroke: vertical
diplopia,
dizziness, RUE
and RLE
ataxia, gait
ataxia,
nausea,
vomiting, and
dysarthria
CT - Acute /
Subacute
bilateral
cerebellar
and R
occipital
infarcts
L VA; 70% 9 Uncomplicated procedure.
Decreased pain sensation right
arm and leg, left face numbness
after procedure. MR showed
left lateral medullary infarct
(perforator) and small R
cerebellar infarct (maybe
subacute from qualifying event
versus embolus to R cerebellum
supplied by jailed L PICA
– supplies both PICA
territories).
Occlusion of
local perforator
to medulla
mRS 1
(1 at study
entry)
3 67/M TIAs: cortical
blindness,
dizziness,
nausea,
vomiting,
facial tingling,
LUE and LLE
numbness
MR – No
acute
infarcts. Old
L pontine
infarct.
Basilar;
80%
4 Uncomplicated procedure.
New diploplia, dysarthria, L sided
weakness, L arm numbness.
MR – isolated acute R pontine
infarct
Occlusion of
local perforators
to pons
mRS 2
(0 at study
entry)
4 60/F Stroke: perioral
numbness, L
face, arm and
leg numbness
and left
hemiparesis.
No MR or CT
submitted
but records
indicate “R
basal
ganglia”
infarct
R M1;
69%
6 Uncomplicated procedure. Pre
and post angio images are
unsubtracted (Figure 1)
New left face and arm
weakness. MR shows new infarct
in R basal ganglia, internal
capsule, and corona radiate
(perforators), and infarcts of
insula and temporal/
parietal lobes (distal emboli)
Occlusion of
Local
Lenticulostriate
perforators
mRS 3
(0 at study
entry)
5 65/F Stroke: non-
specific
bilateral blurry
vision,
dizziness,
nausea,
vomiting, LUE
weakness and
headache
MR - Acute /
Subacute
bilateral
cerebellar
and Rmedial
temporal
lobe infarct
L VA –
Basilar
Junction;
89%
10 Uncomplicated procedure. Pre
image (Figure 1) shows no flow
beyond AICAs and
microcatheter through stenosis
Patient awoke from anesthesia
with encephalopathy, the
following morning increased LUE
weakness. MR shows new R
pontine infarct (perforator) and
bilateral cerebellar infarcts
(proximal PICA and distal
AICA/SCA emboli) and small R
temporal and R occipital infarcts
(distal emboli, not shown)
Occlusion of
local perforators
to pons
mRS 4
(3 at study
entry)
6 78/M Stroke:
confusion,
bilateral blurry
vision,
dizziness, R
face/UE/LE
numbness and
weakness,
RUE/LE ataxia,
gait ataxia,
oscillopsia,
dysarthria
CT – No
infarcts
Basilar;
80%
7 Uncomplicated procedure.
Worsening symptoms after
stenting including newly reported
L arm and leg ataxia, left arm
weakness, and R face numbness.
MR shows L pontine infarct
(perforator), small R cerebellar
infarct (probable embolus to
jailed R AICA), and small L
thalamic infarct (distal embolus)
Occlusion of
local perforators
to pons
mRS 4
(2 at study
entry)
7 55/M TIA: bilateral
blurred vision,
dysarthria,
ataxia
CT - 1 month
earlier
showed no
infarcts. No
brain
imaging
after TIA.
L VA; 81% 22 No plavix load AND ACT not
monitored (protocol deviation).
Occlusion of the left SCA during
procedure (Figure 1, post image)
LUE and LLE dysmetria after
stenting. MR shows L cerebellar
infarct (embolus to L SCA) and
small inferior vermian infarction
(embolic, L AICA supplies midline
inferior vermis)
Distal embolism mRS 1
(0 at study
entry)
8 74/M TIA: 2 episodes
on the same
day consisting
of dizziness
and gait
ataxia lasting
1–2 minutes
MR – no
infarcts
Basilar;
87%
22 Challenging procedure with
difficult access.
Slurred speech, horizontal
diploplia, R arm/leg/face
weakness hours after the
procedure. MR shows infarct in L
pons (perforators), small bilateral
cerebellar infarcts (proximal PICA
and distal SCA emboli), and
small R occipital infarct (distal
embolus, (not shown))
Occlusion of
local perforators
to pons
mRS 2
(1 at study
entry – not
stroke
related)
9 59/M Stroke:
bilateral blurry
vision,
diploplia,
dysarthria,
disorientation,
and
headache
MR – acute /
subacute
infarcts in
both
occipital
lobes, both
cerebellar
hemispheres
and L medial
temporal lobe
Basilar;
74%
13 Uncomplicated procedure.
Slurred speech, R hemiparesis.
MR shows new infarct in L pons
(perforator), L cerebellar infarct
(embolus to jailed L AICA), and
small, left thalamic infarct (distal
embolus)
Occlusion of
local perforators
to pons
mRS 3
(1 at study
entry)
10 71/F Stroke:
dizziness, gait
ataxia,
weakness of L
UE and LLE
MR - no
acute /
subacute
infarcts. Old
L pontine
and L
thalamic
infarcts
Basilar;
77%
4 Uncomplicated
Difficulty reading/vision loss after
procedure. L homonymous
hemianopia
CT shows right occipital infarction
Distal embolism mRS 1
(2 at study
entry)
11 61/F Stroke:
aphasia,
confusion, RUE
and RLE
weakness
No MR
submitted
for central
review. Site
review -“
subcortical
ischemia in
LMCA
territory”
Proximal
L M1;
72%
14 Post-Stent placement L ACA
occluded and multiple distal L
MCA emboli (not shown)
New right hemiplegia. MR shows
large confluent infarct involving
caudate, putamen, and capsule
(perforator) and infarcts of the L
frontal, L parietal and L temporal
lobe (distal emboli).
Combined –
occlusion of local
lenticulostriate
perforators and
distal embolism
mRS 5
(3 at study
entry)
12 68/F TIA: speech
arrest and RUE
weakness
lasting 10–15
minutes.
Several
episodes of R
arm weakness
and aphasia 2
months prior,
one of which
“associated
with small
acute infarct”.
MR – acute
L frontal and
L corona
radiate/
centrum
semi-ovale
infarcts (so
this patient’s
presenting
TIA was
actually a
cerebral
infarct with
temporary
signs (CITS)
L M1;
68%
18 Uncomplicated procedure.
Post-procedure mild dysarthria,
word finding difficulty and RUE
drift. CT shows new infarcts in L
putamen and internal capsule
Occlusion of
local
lenticulostriate
perforators
mRS 1
(2 at study
entry – not
related to
qualifying
event)
13 64/F TIA: 1st episode
5 minutes of
vertigo, 2nd
episode 2
hours of gait
ataxia and
dysarthria.
MR - no acute/
subacute
infarcts but
did show old
infarcts in
bilateral
pons, R
thalamus, R
parietal and
R putamen /
capsule
Basilar;
66%
4 Uncomplicated procedure per
report.
Intubated for 48 hours, POD#2
New LUE and LE weakness. CT
shows evolving right pontine
infarct
Occlusion of
local perforators
to
pons
mRS 2
(1 at study
entry)
14 46/M TIA: R sided
blurry vision,
RUE and RUE
ataxia,
dysarthria, and
peri-oral
numbness
MRI –acute
/subacute
infarcts
Basilar;
75%
3 Uncomplicated procedure.
Post-op: dizziness, dysarthria,
nystagmus, no motor deficit.
CT showed new R cerebellar
infarct
6 days later right face weakness,
dysarthria worse, ataxia. MR
shows infarct in L pons
(perforators), small R cerebellar
infarct (emboli to jailed R AICA),
and L mesial temporal infarct
(distal embolus)
Occlusion of
local perforators to
pons
mRS 2
(0 at study
entry)
Delayed
Stroke
15 74/F Stroke: L face
weakness and
LUE numbness
MR – acute
/subacute
infarcts in R
frontal and
parietal
lobes
R M1;
75%
11 Uncomplicated procedure. Awoke
stable
L arm weakness 36 hours later.
MR showed a small R
putamen/internal capsule
(perforator)
Occlusion of
local
lenticulostriate
perforators
mRS 1
(0 at study
entry)
16 71/F Stroke: L facial
and LLE
weakness
MR – acute
/subacute
infarcts of
the R
caudate
and R frontal
and parietal
lobes
R ICA;
70%
4 Delayed filling of insular
branches noted at baseline that persisted post-stent. Systemic
integrelin
started
4 days after stent developed left
hemiparesis (0/5 LUE, 3/5 LLE), R
gaze preference, mild neglect, L
homonymous hemianopia. Repeat
angiogram showed stent occlusion
(Final angio in Figure).
Delayed Stent
Thrombosis
mRS 4
(0 at study
entry)
17 58/F Stroke
(followed by
TIA) : left
homonymous
hemianopia,
dysarthria, left
face numbness
and L face
weakness
MR – acute
infarcts of R
frontal,
parietal and
temporal
lobes
R ICA;
75%
6 Angioplasty X 2 and stent.
Uncomplicated. Awoke stable.
6 days later, R sided headache,
left hemiplegia. CT at outside
hospital showed R hyperdense
MCA sign (not shown) and large
infarcts of R frontal, parietal and
temporal lobe
Probable
Delayed Stent
Thrombosis
Not done
at 30 days
but mRS 3
at 90 days
(3 at study
entry)
18 74/F Stroke:
aphasia,
confusion and
RLE weakness
CT – acute /
subacute
infarcts of L
frontal and
parietal
lobes
L ICA;
69%
10 Stent required post-dilation
Thrombus forming on stentand in
A1 segment at delayed
angiogram (10 mins)
administered IV abciximab.
Persisted at 20 minuntes, gave IA
tPA (5.4 mg). Neurological
baseline after
extubated
Pt found down by husband 4
days after procedure with R
hemiplegia and aphasia. Stent
open on repeat angiogram. MR
showed extensive L MCA, ACA
and R ACA embolic lesions
Distal emboli mRS 4
(2 at study
entry)
19 77/F Stroke:
presented with
dizziness and
loss of
consciousness.
Exam showed
gait ataxia,
RUE and R LE
weakness, and
R face and R
UE numbness
MR – acute
/subacute
infarcts of
bilateral
cerebellum
and R
medulla
Basilar;
78%
4 Difficult access (radial
approach) otherwise
uncomplicated
6 days after procedure,
Diplopia, bilateral UE ataxia,
nystagmus, R face sensory loss, L
leg numbness. MR showed new
bilateral pontine infarcts
(perforators) and small bilateral
cerebellar infarcts (emboli to
jailed bilateral AICA)
Occlusion of
local perforators to pons plus
emboli to jailed
bilateral ICAs
mRS 4
(3 at study
entry)
CITS
20 77/ M Stroke: vertigo,
dysarthria, R
hemiparesis,
confusion.
Good response
to tPA with
residual mild
dysarthria and
R leg weakness
MR – no
acute /
subacute
infarcts
Basilar;
89%
Uncomplicated. Right brachial
approach
Transient weakness of R arm
night of procedure that resolved
by next morning. MR showed
large R cerebellar infarct (jailed AICA
embolism) and L small
pontine
infarcts (perforators)
Embolus to
jailed AICA
mRS 0 0 at
30 days (mRS 0 at
study entry)
21 61/F Stroke: aphasia
and R face
weakness
MR – acute
/subacute L
frontal and
parietal
infarcts
L M1;
70%
Uncomplicated
3 weeks post procedure,
transient “new L hemisphere
symptoms”. MR showed new
small L corona
radiata infarct
Occlusion of
local perforators
mRS 3 at 30
days
(2 at study
entry)

Infarct size: 1.5 cm or less – small, 1.5 to 3.0 cm – medium. No petechial hemorrhage unless otherwise noted. Corresponding images pre and post angioplasty and stenting and follow up brain imaging showing the ischemic infarctions described in the “Procedural and Stroke Details” are shown in Figure 1 by patient number, unless indicated otherwise.

M = male; F = female; MR = magnetic resonance; CT = computed tomography; mRS = modified Rankin score; QE = Qualifying event; AICA = anterior inferior cerebellar artery; MCA = middle cerebral artery; ACA = anterior cerebral artery; M1 – first segment of the MCA, A1 – first segment of the ACA; VA = vertebral artery; L = left; R =right; PICA = posterior inferior cerebellar artery; UE = upper extremity; LE = lower extremity; IA = intra-arterial; % stenosis = central reading

Five patients had a delayed ischemic event (patients 15 −19). All delayed events occurred within 6 days of the procedure. One of these events was a local perforator stroke only (patient 15, at 36 hours). One patient had a complete stent thrombosis at four days (patient 16), one had a probable stent thrombosis at 6 days (patient 17), one had extensive distal emboli at 4 days (patient 18), and one had mixed perforator and distal embolic strokes at 6 days (patient 19).

Both of the CITS events were related to local perforator or branch (jailed AICA) vessel occlusions (patients 20 and 21). One was in the early post-operative period and the other occurred three weeks after the procedure.

Delayed Intraparenchymal Hemorrhage

Seven patients had primarily parenchymal hemorrhage (IPH) (Table 3, patients 22–28, Figure 2). Six were endpoint events with symptoms lasting more than 24 hours: one was noted 2 hours after the procedure (patient 27) and five were noted when neurological signs developed several hours after PTAS. In the 7 patients with IPH, baseline brain imaging showed infarcts in five (two presenting with ischemic strokes (patients 25 and 28) and three presenting with CITS (patients 23, 24 and 27). The remaining two had either a normal CT (patient 22) or no imaging (patient 26) at baseline. All IPHs were distributed within the vascular territory of the treated artery. Of the six symptomatic IPHs, four were fatal, one resulted in a modified Rankin score (mRS) of 5, and one resulted in a mRS of 2 at 90 days. One patient had a cerebellar hemorrhage with transient post-operative nausea but no symptoms at 24 hours (patient 28).

Table 3.

Intraparenchymal Hemorrhage

Patient
Numb
er
Age/
Gend
er
Qualifyin
g Event
Baseline
Imaging
Location
of
Stenotic
Artery
Parent
artery
diamete
r (per
site)
Timing and Details
of Procedure
Post-Procedural details 30-day
Modified
Rankin
Scale
22 59/F TIA:
recurrent
episodes
of
aphasia
and
weakness
CT (3 days
later):
Normal
M1 2.90 mm 4 days after TIA.
Uncomplicated.
Extubated on
table, normal
neurological
examination
9 hours post procedure
developed aphasia
and hemiplegia. CT
showed hemorrhage in
revascularized territory.
Went to OR for
evacuation.
5
23 70/M TIA (CITS):
mild
pontine
stroke 6
weeks
prior,
then
transient
dysarthria
TIA
MR (same
day as CITS):
small
medullar
and pontine,
two medium
cerebellar
acute
infarctions
VA 3.00 mm 6 days after CITS.
Uncomplicated.
Isolated VB
system with
occluded
contralateral
vertebral artery
distal to PICA.
Extubated in
angio with
unchanged
baseline
neurological
examination on
arrival to ICU
Hours (time not
documented) after
procedure in ICU
became drowsy, then
acutely hypertensive
and lost brainstem
reflexes. CT showed
bilateral cerebellar IPH,
with secondary IVH and SAH and
obstructive
hydrocephalus (not
shown). Went to OR
emergently for
decompressive
craniectomy
Died 11
days
after
procedure
24 46/M TIA (CITS):
Upper
extremity
weakness
MR (1 day
post CITS):
small
parietal and
corona
radiata,
medium
frontal acute
infarctions
Petrous
ICA
4.38 mm 20 days after CITS.
Uncomplicated.
Fetal PCA
2 days post procedure.
Sudden onset weakness
and confusion at home
after discharge. CT
showed thalamic IPH (in
territory of fetal PCA)
with ventricular
extension. Required
with ventricular
extension. Required
urgent urgent EVD.
1
25 76/F Stroke:
Word-
finding
diffiulties
MR (same
day): small
frontal and
medium
corona
radiate
acute
infarctions.
Old small
putamen
infarct with
petechial
hemorrhage
M1 2.18 26 days after
stroke.
Uncomplicated.
Extubated with
unchanged
baseline
neurological
examination
12 hours after
procedure became
acutely hemiparetic
and aphasic. Urgent
CT showed large ICH
with local SAH in the
revascularized territory.
Family withdrew care.
Died 3
days
after
procedu
re
26 52/M TIA: Face,
arm, leg
weakness
and
dysarthria
None
available
Supracli
noid ICA
3.03 28 days after TIA.
Uncomplicated.
Extubated in
angio with
unchanged
normal
neurological
examination
7 hours after procedure.
CT showed 7 cm ICH
with herniation and
shift.
Died 1
day
after
procedu
re
27 60/F TIA (CITS):
Face and
arm
weakness,
aphasia
MR (same
day): small
frontal,
temporal
and
caudate,
medium
temporal
and parietal infarctions.
M1 2.20 8 days after CITS.
Uncomplicated.
Extubated with
normal baseline
neurological
examination
2 hours after procedure.
Became acutely
hypertensive with
neurological decline.
CT showed large ICH in
territory. Progressed
rapidly to brain death.
Died 1
day
after
procedu
re
Asymptomatic
28 73/M Stroke:
Diploplia,
ataxia,
arm and
leg
weakness
MR (sme
day): small
occipital,
thalamic
and bilateral
cerebellar
acute
infarctions
Basilar 3.48 3 days after
stroke.
Uncomplicated.
12 hours after
procedure. Transient
nausea. No new deficit.
CT showed 3.5 cm
cerebellar ICH
1

Infarct size: 1.5 cm or less – small, 1.5 to 3.0 cm – medium. No petechial hemorrhage unless otherwise noted . The pre and post angioplasty and stenting angiographic images corresponding to the procedure description are shown in Figure 2 by patient number. Representative CT images showing the location and extent of hemorrhage (described in the post-procedure detail column) are shown in Figure 2 as well, unless otherwise indicated. M = male; F = female; MR = magnetic resonance; CT = computed tomography; mRS = modified Rankin score; QE = Qualifying event;

Procedural Subarachnoid Hemorrhage

Subarachnoid hemorrhage (SAH) occurred in six patients (Table 4, patients 29–34, Figure 2). Three patients had wire perforations that were evident during the procedure (patients 29, 30, and 32). The clinically adjudicated endpoint for patient 32 was an ischemic stroke: the perforation was successfully treated with coil embolization of the injured arterial branch. This resulted in a clinical ischemic stroke (adjudicated and reported as ischemic stroke in the original primary analysis). A fourth patient (patient 33) had acute SAH during the procedure but the etiology could not be ascertained. One patient with interval occlusion between randomization and the endovascular procedure was treated with angioplasty alone (patient 31, protocol violation). This resulted in a vessel rupture (post plasty angio showing active extravastion). One final patient (patient 34) had an asymptomatic SAH identified on post-operative CT. No cause was determined.

Discussion

Angioplasty and stenting of intracranial arteries is an emerging, but as yet unproven, therapy for stroke risk reduction for patients with recently symptomatic ICAD. The SAMMPRIS study was the first randomized trial of this procedure for ICAD. Angioplasty and stenting in this trial was associated with a higher than expected rate of perioperative stroke. Reduction or prevention of these complications will be required for this procedure to be proven safe and effective. The purpose of this study was to perform a detailed, post-hoc review of all complications that occurred in the stenting arm, in an effort to categorize and attribute the mechanism of stroke for each patient.

The most frequent types of stroke observed in the SAMMPRIS trial were local perforator ischemic strokes (n=12), primary intraparenchymal hemorrhage (n=7), and subarachnoid hemorrhage (n=6). Distal symptomatic embolic stroke as an immediate complication of angioplasty and stenting was uncommon.

Local perforator stroke after angioplasty and/or stenting has been described in prior case series. Prior investigators have reported an association of a higher risk of procedural ischemic stroke with posterior versus anterior circulation lesions after angioplasty and stenting.69 Jiang and colleagues reported a 13% (9/69) 30-day risk for stroke after angioplasty and stenting of symptomatic basilar artery stenoses in a review of outcomes from a large single institution series.10 However, this study did not categorize these strokes as either embolic or local perforator. Perforator occlusion by the displaced or disrupted atheromatous debris (snow-plowing) has been postulated as the mechanism for regional perforator stroke after stenting.11 Potential approaches to reduce this risk of this phenomenon may include performing angioplasty alone rather than angioplasty and stenting 11 or using high-resolution MR vessel wall imaging for treatment planning or patient selection. 2, 12, 13 Even if the risk of perforator stroke after stenting could be reduced, aggressive risk factor management for patients with evidence of unstable or ruptured plaques adjacent to perforator-rich vessel segments may remain more effective than mechanical intervention.

Parenchymal hemorrhage occurred with a higher than expected frequency, compared to prior case series. In the U.S. Wingspan Registry, Fiorella and colleagues reported five major events in 78 patients.14 Two were vessel perforations resulting in death, one was an IPH, and two were embolic ischemic strokes.9 In the NIH wingspan registry, Zaidat and colleagues reported two IPHs in 129 patients.15 In SAMMPRIS, Fiorella, et al, reported that delayed IPH was independently associated with higher baseline percent stenosis as well as the combination of a high procedural ACT (> 300 seconds) and a loading dose of clopidogrel. The mechanism of IPH post stenting in SAMMPRIS patients is uncertain, but the relationship between severe stenosis and hemorrhage suggests the possibility of hyperperfusion or autoregulatory dysfunction as a mechanism. 16 However, the time course and clinical features are different from the typical hyperperfusion syndrome seen after extracranial carotid revascularization. 17

The etiology of the subarachnoid hemorrhages was clear in most of the cases. These could be attributed to wire perforation in three and vessel rupture in one. The vessel rupture occurred in a patient with a completely occluded segment (interval occlusion between enrollment and the angioplasty procedure) and was a protocol violation. These events were potentially avoidable. The Wingspan system requires several exchanges of catheters over a 300 cm exchange wire. The wire tip may move into small distal branches and perforate for a number of technical reasons. One is lack of attention to detail by the operator. Another is related to inadequate guide catheter support leading to abrupt movement of the system. These complications could potentially be reduced with experience, although no relationship between hemorrhage and physician experience was found in the SAMMPRIS trial. 3 These complications may also be reduced with angioplasty alone or angioplasty and stenting with devices that do not require exchanges.

The SAMMPRIS protocol did not include any tests of platelet function. The study policy disallowed resistance testing after randomization to avoid the use of antiplatelet agents or doses that were not specified by the protocol. It is unknown whether the patients with ischemic events were more resistant to aspirin or clopidogrel, or if the patients with hemorrhagic events were less resistant to the antiplatelet regimen.

This retrospective study is subject to a number of limitations, most significantly that of the attribution of stroke mechanism. This process was post-hoc, based on review of available images and clinical data, and admittedly inexact. For ischemic stroke, stroke mechanism was based primarily on brain imaging and clinical symptoms. Many of the patients that were categorized as perforator stroke also had distal lesions on DWI. While it is likely that many of these represent emboli from the procedure, the clinical relevance of asymptomatic DWI lesions is unclear. 18 Parenchymal hemorrhage was separated from subarachnoid hemorrhage based on review of imaging and the timing of the clinical event. It is possible, however, that some of the parenchymal hemorrhages were related to wire perforation.

Conclusion

The most frequent causes of peri-operative stroke in the SAMMPRIS trial were perforator-territory ischemic stroke, reperfusion hemorrhage, and subarachnoid hemorrhage. Future trials of intracranial angioplasty and stenting will need to reduce these events in order to establish the safety and efficacy of this procedure.

Supplementary Material

1

Acknowledgments

Funding:

The SAMMPRIS trial was funded by a research grant (U01 NS058728) from the US Public Health Service National Institute of Neurological Disorders and Stroke (NINDS). In addition, the following Clinical and Translational Science Awards, funded by the National Institutes of Health, provided local support for the evaluation of patients in the trial: Medical University of South Carolina (UL1RR029882), University of Florida (UL1RR029889), University of Cincinnati (UL1RR029890), and University of California, San Francisco (UL1RR024131).

Corporate Support: Stryker Neurovascular (formerly Boston Scientific Neurovascular) provided study devices and supplemental funding for third party device distribution, site monitoring and study auditing. This research is also supported by the Investigator-Sponsored Study Program of AstraZeneca that donates rosuvastatin (Crestor) to study patients.

Financial Support and Industry Affiliations:

Drs. Fiorella, Derdeyn, Turan, Janis, and Chimowitz, Michael Lynn M.S, and Bethany Lane RN serve on the Executive Committee of the SAMMPRIS trial which is funded by the National Institute of Neurological Disorders and Stroke (grant number: U01 NS058728). All receive salary support from the SAMMPRIS grant. All other authors were investigators in SAMMPRIS and were reimbursed from the SAMMPRIS grant for their effort. The following investigators report additional support:

Colin Derdeyn MD receives grant support from the NINDS (P50 55977; R01 NS051631). He is also on the Scientific Advisory Board for W.L Gore and Associates and is the Chair of the Scientific Advisory Board for Pulse Therapeutics.

David Fiorella MD, PhD has received institutional research support from Seimens Medical Imaging and Microvention, consulting fees from Codman/Johnson and Johnson, NFocus, W.L. Gore and Associates, and EV3/Covidien, and royalties from Codman/Johnson and Johnson. He has received honoraria from Scientia and has ownership interest in CVSL and Vascular Simulations.

Michael J. Lynn, MS receives grant support from the National Eye Institute. He is the principal investigator of the Coordinating Center for Infant Aphakia Treatment Study (EY013287) and a co-investigator on the Core Grant for Vision Research (EY006360).

Harry J. Cloft, MD, PhD has received research support for the SAPPHIRE Carotid Stent registry.

Bethany F. Lane RN has received consulting fees from Microvention Terumo.

Tanya N. Turan, MD is a past recipient of funding from the American Academy of Neurology (AAN) Foundation Clinical Research Training Fellowship and is the current recipient of a K23 grant from NIH/NINDS (1 K23 NS069668-01A1). She has also served as an expert witness in medical legal cases.

Scott Janis PhD is a program director at the National Institute of Neurological Disorders and Stroke.

Marc Chimowitz, MBChB has received research grants from NINDS to fund the WASID trial (1 R01 NS36643) and to fund other research on intracranial stenosis (1 K24 NS050307 and 1 R01 NS051688). He currently serves on the stroke adjudication committee of an industry funded osteoporosis drug trial (Merck and Co., Inc.) and on the DSMB of another industry funded patent foramen ovale closure trial (W.L Gore and Associates) and is compensated for those activities. He has also served as an expert witness in medical legal cases.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplemental content: SAMMPRIS Trial Investigators

The authors present a very straightforward analysis of the data acquired for the SAMMPRIS trial. Primarily a descriptive study, this analysis describes with some additional detail the potential etiologies for periprocedural complications in angioplasty and stenting. Interestingly, as previously described, the authors suggest that posterior circulation (in particular, basilar artery) procedures carry the majority of complication risk secondary to vessel perforation, perforator obstruction and hemorrhagic conversion. Thus, this retrospective analysis reiterates the significant risks incurred in posterior circulation atheromatous disease and emphasizes the need for proper patient education with a realistic discussion of risks and benefits to these patients and families. Unfortunately, there is no clear discussion as to potential modifications that should or could be made in techniques or in devices.

The authors provide an excellent platform from which to begin the “deep dive” in data analysis of not only their own practice data, but for future studies that will help practitioners in this field better understand patient selection and complication avoidance for patients with intracranial (specifically posterior circulation) atheromatous disease refractory to medical management.

Charles J. Prestigiacomo, Newark, New Jersey

References

  • 1.Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365:993–1003. doi: 10.1056/NEJMoa1105335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Fiorella D, Derdeyn CP, Lynn MJ, et al. Detailed Analysis of Periprocedural Strokes in Patients Undergoing Intracranial Stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Stroke. 2012 doi: 10.1161/STROKEAHA.112.661173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Derdeyn CP, Fiorella D, Lynn MJ, et al. Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. Journal of NeuroInterventional Surgery. 2012 doi: 10.1136/neurintsurg-2012-010504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chimowitz MI, Lynn MJ, Turan TN, et al. Design of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial. J Stroke Cerebrovasc Dis. 2011;20:357–368. doi: 10.1016/j.jstrokecerebrovasdis.2011.05.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Turan TN, Lynn MJ, Nizam A, et al. Rationale, Design, and Implementation of Aggressive Risk Factor Management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. Circulation Cardiovascular quality and outcomes. 2012;5:e51–e60. doi: 10.1161/CIRCOUTCOMES.112.966911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Nahab F, Lynn MJ, Kasner SE, et al. Risk factors associated with major cerebrovascular complications after intracranial stenting. Neurology. 2009;72:2014–2019. doi: 10.1212/01.wnl.0b013e3181a1863c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jiang WJ, Du B, Hon SFK, et al. Do patients with basilar or vertebral artery stenosis have a higher stroke incidence poststenting? journal of NeuroInterventional Surgery. 2010;2:50–54. doi: 10.1136/jnis.2009.000356. [DOI] [PubMed] [Google Scholar]
  • 8.Gröschel K, Schnaudigel S, Pilgram SM, Wasser K, Kastrup A. A Systematic Review on Outcome After Stenting for Intracranial Atherosclerosis. Stroke. 2009;40:e340–e347. doi: 10.1161/STROKEAHA.108.532713. [DOI] [PubMed] [Google Scholar]
  • 9.Jiang WJ, Srivastava T, Gao F, Du B, Dong KH, Xu XT. Perforator stroke after elective stenting of symptomatic intracranial stenosis. Neurology. 2006;66:1868–1872. doi: 10.1212/01.wnl.0000219744.06992.bb. [DOI] [PubMed] [Google Scholar]
  • 10.Jiang W-J, Du B, Hon SFK, et al. Do patients with basilar or vertebral artery stenosis have a higher stroke incidence poststenting? Journal of NeuroInterventional Surgery. 2010;2:50–54. doi: 10.1136/jnis.2009.000356. [DOI] [PubMed] [Google Scholar]
  • 11.Levy EI, Hanel RA, Boulos AS, et al. Comparison of periprocedure complications resulting from direct stent placement compared with those due to conventional and staged stent placement in the basilar artery. Journal of Neurosurgery. 2003;99:653–660. doi: 10.3171/jns.2003.99.4.0653. [DOI] [PubMed] [Google Scholar]
  • 12.Vergouwen MD, Silver FL, Mandell DM, Mikulis DJ, Krings T, Swartz RH. Fibrous cap enhancement in symptomatic atherosclerotic basilar artery stenosis. Archives of neurology. 2011;68:676. doi: 10.1001/archneurol.2011.89. [DOI] [PubMed] [Google Scholar]
  • 13.Shi M, Wang S, Zhou H, Cheng Y, Feng J, Wu J. Wingspan stenting of symptomatic middle cerebral artery stenosis and perioperative evaluation using high-resolution 3 Tesla MRI. Journal of Clinical Neuroscience. 2012;19:912–914. doi: 10.1016/j.jocn.2011.08.027. [DOI] [PubMed] [Google Scholar]
  • 14.Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke. 2007;38:881–887. doi: 10.1161/01.STR.0000257963.65728.e8. [DOI] [PubMed] [Google Scholar]
  • 15.Zaidat OO, Klucznik R, Alexander MJ, et al. The NIH registry on use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology. 2008;70:1518–1524. doi: 10.1212/01.wnl.0000306308.08229.a3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.van Mook WNKA, Rennenberg RJMW, Schurink GW, et al. Cerebral hyperperfusion syndrome. The Lancet Neurology. 2005;4:877–888. doi: 10.1016/S1474-4422(05)70251-9. [DOI] [PubMed] [Google Scholar]
  • 17.Ogasawara K, Sakai N, Kuroiwa T, et al. Intracranial hemorrhage associated with cerebral hyperperfusion syndrome following carotid endarterectomy and carotid artery stenting: retrospective review of 4494 patients. J Neurosurg. 2007;107:1130–1136. doi: 10.3171/JNS-07/12/1130. [DOI] [PubMed] [Google Scholar]
  • 18.Derdeyn CP. Diffusion-weighted imaging as a surrogate marker for stroke as a complication of cerebrovascular procedures and devices. AJNR Am J Neuroradiol. 2001;22:1234–1235. [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES